对α-synuclein的自身抗体抑制了它的聚合和细胞毒性
Carmen Noelker1, Florian Seitz1, Annekathrin Sturn1
1Department of Neurology, Philipps-University Marburg, Rudolf-Bultmann Strasse 8, 35033, Marburg, Germany.
Journal of autoimmunity
|March 4, 2025
概括
对抗α-synuclein (α-Syn) 的自然存在的自身抗体被分离和特征. 这些自身抗体抑制α-Syn纤维素的形成并逆转其毒性,表明潜在的帕金森氏症.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 阿尔法-同核素 (α-Syn) 聚合物形成勒维体,这是帕金森病 (PD) 的标志.
- 最近已经确定了对α-Syn (α-Syn-nAbs) 的自然存在的自身抗体.
- 了解这些α-Syn-nAbs的特性和功能对于PD研究至关重要.
研究的目的:
- 隔离和表征天然存在的对α-Syn (α-Syn-nAbs) 的自身抗体.
- 确定这些α-Syn-nAbs. 的结合特性,表位和功能作用.
- 探索α-Syn-nAbs在帕金森病中的潜在治疗影响.
主要方法:
- 从静脉注射免疫球蛋白 (IVIg) 中分离α-Syn-nAbs,使用α-Syn亲和度列.
- 通过ELISA,西方抹杀和免疫沉来表征结合能力.
- 使用表面等离子体共振 (Biacore) 和通过阵列进行表位图映射来分析结合亲和力.
- 在体外功能测定包括使用神经母细胞瘤细胞的毒性和纤维化抑制.
主要成果:
- α-Syn-nAbs表现出强烈的与α-Syn结合,并进行了详细的亲和力分析.
- 关键结合表位被映射到α-Syn.非粉样成分 (NAC) 区域内的特定序列.
- 这些自身抗体显著抑制了α-Syn纤维素的形成,并在SH-SY5Y细胞中逆转了α-Syn寡合体诱导的毒性.
结论:
- 对α-Syn的自然存在的自身抗体具有显著的结合和功能能力.
- 这些自身抗体干扰帕金森病的关键病理事件,包括纤维细胞的形成和毒性.
- α-Syn-nAbs是开发新型帕金森病治疗方法的有希望的候选者.
相关概念视频
Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K
Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28


